RxDoctor Payments Data

Davida Prater

Acute Care · Beavercreek, OHNPI 1447287230

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Gilead at 55.7% of the total. Reporting peaked in 2022 at $16,694 and has fallen 64.2% since, to $5,974 in 2024. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,888in general payments, 2019–2025

Across 191 payments — averaging $240.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$26K
  • AbbVie$19K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$248
  • Johnson & Johnson$201
  • Sanofi$84
  • QOL Medical, LLC$55
  • plus $317 from 12 others

What the payments were for

  • Consulting fees$4,0809%
  • Speaking & faculty fees$25,48056%
  • Travel & lodging$11,75526%
  • Food & beverage$4,47410%
  • Education$990%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,888 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$75,304
Medicare patients
184
Services billed
2,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir13$320,815
MytesiCrofelemer14$35,559
LinzessLinaclotide30$17,826
CreonLipase/Protease/Amylase13$16,636
ErythromycinErythromycin Base13$5,805
Dexlansoprazole DrDexlansoprazole17$4,803
Sucralfate21$4,028
Colestipol Hcl29$1,468
Omeprazole155$1,285
Dicyclomine Hcl46$1,164
Pantoprazole Sodium140$1,135
Promethazine Hcl13$379
Famotidine28$345
Ondansetron Hcl26$308
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa$25,560$320,81513 claims
AbbVieLinzess, Creon$19,423$34,46143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Beavercreek

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →